Cystic fibrosis‐related mortality trends in Mexico between 1999 and 2020

Bustamante, Adriana; Fernández, Lucía T; Rivas, Lissette C; Mercado-Longoría, Roberto

doi:10.1002/ppul.26239

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La expectativa de vida contrasta entre los países desarrollados versus países con economías emergentes (EE); para 2020, la Fundación FQ en EE.UU., y el Registro europeo de FQ reportaron un promedio de edad al momento de la muerte 34.1 años y 32 años, respectivamente. En contraparte, la FQ en países de EE sigue estando relacionada con una menor supervivencia; en México, con base en el registro 2016–2020, la supervivencia fue de 15.5 años [7]. Por tanto, urge fortalecer políticas públicas de salud en favor del diagnóstico temprano con el objetivo de establecer equipos multidisciplinarios dotados plenamente para realizar evaluaciones durante primeros años de vida, del mismo modo, solventar el acceso al tratamiento que impacte en la supervivencia y la calidad de vida.…”

Section: Transferencia En La Práctica De Dra Esperanza Figueroa-hurta...unclassified

Fibrosis quística: Facilitar urgentemente el acceso al diagnóstico temprano también en los países emergentes

Figueroa-Hurtado,

Ortiz-Farías,

Cortés-Telles

2023

Kompass Neumol

View full text Add to dashboard Cite

Background: The Cystic Fibrosis Foundation Patient Registry (CFFPR) reports a high prevalence of asthma (34.6%) in people with Cystic Fibrosis (PwCF). While our current understanding of this relationship is limited, a type 2 inflammatory (T2) phenotype has often been identified in CF patients. Research question: This study aimed to evaluate the relationship between the eosinophilic CF T2 inflammatory phenotype and CF-related pulmonary outcomes and microbiological data. Study design: and methods: We conducted a retrospective chart review of adult patients with CF (18 and older; n = 93) receiving their care at University of Virginia Medical Center adult program from January, 2013 through December, 2018. Data collected included demographic data, CFTR (CF transmembrane conductance regulator) mutation, CF comorbidities, medications, Absolute Eosinophil Counts (AEC) in cells/µL and Immunoglobulin E (IgE) levels in IU/mL. Results: Of 93 patients screened for study eligibility, 74 were included in the final analysis; 19 patients were excluded due to lack of longitudinal data across the study timeline. Lung function decline correlated with increased AEC (p < 0.001) and IgE (p < 0.001) even when adjusting for covariates: age, gender, presence of Pseudomonas spp., MRSA, other bacterial spp., Aspergillus spp., and other fungi (p < 0.001). Univariate analysis demonstrated that people with CF who experienced more than 2 exacerbations requiring hospitalizations and/or intravenous antibiotics a year were more likely to have high AEC (p = 0.018). Logistic regression showed that as AEC increases, the probability that the measurement was taken during a CF exacerbation increases (p = 0.0039). A linear mixed model showed that each additional annual exacerbation event increased on average the log IgE by 0.04. (p = 0.015). This finding remained stable in a multivariate model (p = 0.0145). When adjusted for atopy, log IgE increases as the number of exacerbation events increases (p = 0.022). There was no association between AEC and IgE and microbiological colonization.

show abstract

Section: Transferencia En La Práctica De Dra Esperanza Figueroa-hurta...unclassified